Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments

Table 7 Prognostic scores before the first transarterial chemoembolization

HAP (0 to 4 points)		NIACE (0 to 7 points)		STATE
Before the first TACE
Albumin < 36 g/dL	1 point	≥ 3 nodules	1 point	Albumin (g/L)
Bilirubin > 17 mcmol/L	1 point	infiltrative HCC vs nodular HCC	1.5 points	-12 (tumour load exceeding the up-to-7 criteria)
			0
AFP > 400 ng/mL	1 point	AFP ≥ 200 ng/mL	1.5 points
		Child-Pugh A vs Child-Pugh B	0
			1.5 points
Size of dominant tumour > 70 mm	1 point	ECOG PS ≥ 1	1.5 points	-12 (if CRP ≥ 1 mg/dL)
No chemoembolization
≥ 2 points		> 3 points		< 18 points

HAP: Hepatoma arterial-embolisation prognostic; AFP: Alpha-fetoprotein; TACE: Transarterial chemoembolization; HCC: Hepatocellular carcinoma; ECOG: Eastern Cooperative Oncology Group; PS: Performance status; CRP: C reactive protein; STATE: Selection for transarterial chemoembolisation treatment.